SELECT
» Biotechnology facts and figures
» Drugs in development
» Key Technologies
DISEASES
» Anemia (2005)
» Breast Cancer (2007)
» Cardiovascular Diseases (2007)
» Diabetes (2005)
» Growth Hormone Deficiency (2005)
» Haemophilia (2005)
» Hepatitis B (2005)
» Inflammatory Bowel Disease (2007)
» Lymphomas (2005)
» Multiple Sclerosis (2005)
» Rheumatoid Arthritis and other Inflammatory Rheumatism (2007)
Biotechnology for
Multiple Sclerosis (2005)
<table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">The disease</span><br> <span class="rteColumn">Multiple sclerosis is an inflammatory disease characterized by the progressive destruction of nerve sheaths in the brain and spinal cord. </span> <a href="more.php?diseaseid=2&bloc=1" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">How many people are affected ?</span><br> This disease affects women in particular (approximately twice as many as men) and young adults (with a peak around the age of 35). Approximately 50,000 people in France and 2.5 million people throughout the world are affected. <a href="more.php?diseaseid=2&bloc=2" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">How many people die from the disease?</span><br> Currently updated... <a href="more.php?diseaseid=2&bloc=3" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Living with the disease</span><br> Multiple sclerosis is the second cause of neurological handicap in young people after road accidents. Symptoms are varied: sensory or motor deficiencies, disorders of vision and balance. <a href="more.php?diseaseid=2&bloc=4" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> <tr> <td><span class="diseaseSubTitle">Treatment <font color='#FFFFFF' size=-2>Témoignage patient de Olga Multiple Scerosis</font> </span></td> </tr> <tr> <td><span class="diseaseText"><img src="../images/pix.gif" width="1" height="10"></span></td> </tr> </table> <table border="0" cellspacing="0" cellpadding="5"> <tr> <td valign="top" bgcolor="#B9E3FF"> <span class="diseaseSubTitle2">Traditional approach</span><br> Before the development of interferon beta, there was no treatment for multiple sclerosis. Injections of cortisone could reduce the intensity and duration of relapses, but had no incidence on the development of the disease itself. <a href="more.php?diseaseid=2&bloc=5" class="lienBleu">More</a></td> <td> </td> <td valign="top" bgcolor="#B9E3FF"> <span class="diseaseSubTitle2">Biotech revolutions</span><br> Even though there is still no cure for multiple sclerosis, the use of interferon beta, made possible using the techniques of biotechnology, has enabled real progress in the long-term treatment of the disease. It was the first drug which had a real effect on the development of the disease. <a href="more.php?diseaseid=2&bloc=6" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/spacer.gif" width="227" height="1"></td> <td><img src="../images/spacer.gif" width="1" height="1"></td> <td><img src="../images/spacer.gif" width="227" height="1"></td> </tr> <tr bgcolor="#B9E3FF"> <td colspan="3"> <span class="diseaseSubTitle2">Drugs currently available</span><br> Two recombinant proteins have been developed, interferon beta 1-a and interferon beta 1-b, with the same properties. The proteins are then introduced into medical preparations put on the market by a number of different pharmaceutical companies. <a href="more.php?diseaseid=2&bloc=7" class="lienBleu">More</a></td> </tr> <tr> <td colspan="3"><img src="../images/pix.gif" width="1" height="5"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Number of patients treated</span><br> The target population for interferon beta is estimated to be 12,000 to 15,000 people in France. <a href="more.php?diseaseid=2&bloc=8" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Future</span><br> A new drug, the monoclonal antibody natalizumab, has just been put on the market in the United States. This, and other treatments still under development, will offer additional solutions for the treatment of multiple sclerosis. <a href="more.php?diseaseid=2&bloc=9" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Costs to society</span><br> The cost of treatment of an MS patient with IFN β’s is in the vicinity of € 15.000 per annum. <a href="more.php?diseaseid=2&bloc=10" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table>
